Brii Biosciences Signed a Licensing Agreement with Joincare Group Image Credits: Vietnam Investment Review Announcement Brii Biosciences, a global biotechnology company known for its excellent therapies for various diseases, has signed a technology transfer and license agreement with Joincare P...
Monte Rosa’s Solution in the Research Article Image Credits: Monte Rosa Therapeutics Inc. Publication Monte Rosa Therapeutics Inc., a global biotechnology company that has discovered molecular glue degrader (MGD) based medicines, introduced discoveries via a research article, featured on ...
Japan’s 3D Bioprinted Human Tissu e Market is Seeking Growth by 2025-2032 Current Status Japan’s 3D Bioprinted Human Tissue Market is concentrating on opportunities and growth in the coming years. The mid-year is focusing on innovation, development, and new engagement in this market t...
SurgiBox Partnered with Ondatec Medical Announcement SurgiBox Inc., a leading medical technology company known for its excellent surgical services, has entered into a partnership agreement with Ondatec Medical, a popular medical device provider in Turkey. This partnership strongly ref...
Pelthos Therapeutics Finalized the Merger Agreement with Channel Therapeutics Announcement Pelthos Therapeutics Inc., a global biopharmaceutical company known for marketing innovative therapeutic products for patients in need, is wrapping up the previous merger agreement with CHRO Merger Sub Inc...
Lixte Biotechnology Holdings Inc.'s Finalization of Securities in the Market Announcement Lixte Biotechnology Holdings, Inc., a pharmaceutical company, closed its private placement with valuable investors for the sale and purchase of $5.0 million of shares of common stock, a series B convertible...
Bluebird, a Center of Attraction What makes a popular equity firm approach a small biopharma firm? The Carlyle Group, along with SK Capital partner, intends to buy bluebird Bio for under $50 million. The Carlyle Group, with its $453 billion in assets under management, and SK Capital partner of $...
Which Company is Investing in Improving a Specific Treatment? Kardium Inc., a founder of the ‘Globe® Pulsed field system’, which is an innovative treatment for atrial fibrillation (AF), has increased its investment to US$250 million. The financing round consists of new investors s...
Gilead's Chances Peak Until GSK’s Response to the Competition Announcement Gilead’s new PreP drug, ‘Yeztugo’, is said to be reaching sales of $4.5 billion, if GSK doesn’t have anything to say about its Apretude medication. Gilead is strengthening its position in the...
BioVersys and Shionogi Joined Forces to Accelerate Research and Development Announcement BioVersys AG, a biopharmaceutical company known for its excellent research and development of antibacterial products for severe infections caused by multidrug-resistant (MDR) bacteria, has signed an exclusiv...
